Asthma control in patients receiving inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation
<p>Abstract</p> <p>Background</p> <p>Although patients have more problems using metered dose inhalers, clinical comparisons suggest they provide similar control to dry powder inhalers. Using real-life situations this study was designed to evaluate asthma control in outp...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-07-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-2466/11/40 |
| _version_ | 1811285165769490432 |
|---|---|
| author | Nicolini Gabriele Bizzi Andrea Losonczy György Eszes Noemi Gálffy Gabriella Müller Veronika Chrystyn Henry Tamási Lilla |
| author_facet | Nicolini Gabriele Bizzi Andrea Losonczy György Eszes Noemi Gálffy Gabriella Müller Veronika Chrystyn Henry Tamási Lilla |
| author_sort | Nicolini Gabriele |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Although patients have more problems using metered dose inhalers, clinical comparisons suggest they provide similar control to dry powder inhalers. Using real-life situations this study was designed to evaluate asthma control in outpatients with moderate to severe persistent asthma and to compare efficacy of fixed combinations of inhaled corticosteroids (ICS) and long acting beta-agonists (LABA).</p> <p>Methods</p> <p>This real-life study had a cross-sectional design. Patients using fixed combinations of ICS and LABA had their asthma control and spirometry assessed during regular visits.</p> <p>Results</p> <p>111 patients were analyzed: 53 (47.7%) received maintenance therapy of extrafine beclomethasone-formoterol (BDP/F) pressurized metered dose inhaler (pMDI), 25 (22.5%) fluticasone-salmeterol (FP/S) dry powder inhaler (DPI), and 33 (29.7%) budesonide-formoterol (BUD/F) DPI. Severity of asthma at time of diagnosis, assessed by the treating physician, was comparable among groups. Asthma control was achieved by 45.9% of patients; 38.7% were partially controlled and 15.3% were uncontrolled. In the extrafine BDF/F group, asthma control total score, daytime symptom score and rescue medication use score were significantly better than those using fixed DPI combinations (5.8 ± 6.2 vs. 8.5 ± 6.8; 1.4 ± 1.8 vs. 2.3 ± 2.1; 1.8 ± 2.2 vs. 2.6 ± 2.2; p = 0.0160; p = 0.012 and p = 0.025, respectively) and the mean daily ICS dose were significantly lower.</p> <p>Conclusions</p> <p>pMDI extrafine BDP/F combination demonstrated better asthma control compared to DPIs formulated with larger particles. This could be due to the improved lung deposition of the dose or less reliance on the optimal inhalation technique or both.</p> |
| first_indexed | 2024-04-13T02:40:18Z |
| format | Article |
| id | doaj.art-57db1d0897114e9c9a5b00ba33304e0d |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-04-13T02:40:18Z |
| publishDate | 2011-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-57db1d0897114e9c9a5b00ba33304e0d2022-12-22T03:06:14ZengBMCBMC Pulmonary Medicine1471-24662011-07-011114010.1186/1471-2466-11-40Asthma control in patients receiving inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulationNicolini GabrieleBizzi AndreaLosonczy GyörgyEszes NoemiGálffy GabriellaMüller VeronikaChrystyn HenryTamási Lilla<p>Abstract</p> <p>Background</p> <p>Although patients have more problems using metered dose inhalers, clinical comparisons suggest they provide similar control to dry powder inhalers. Using real-life situations this study was designed to evaluate asthma control in outpatients with moderate to severe persistent asthma and to compare efficacy of fixed combinations of inhaled corticosteroids (ICS) and long acting beta-agonists (LABA).</p> <p>Methods</p> <p>This real-life study had a cross-sectional design. Patients using fixed combinations of ICS and LABA had their asthma control and spirometry assessed during regular visits.</p> <p>Results</p> <p>111 patients were analyzed: 53 (47.7%) received maintenance therapy of extrafine beclomethasone-formoterol (BDP/F) pressurized metered dose inhaler (pMDI), 25 (22.5%) fluticasone-salmeterol (FP/S) dry powder inhaler (DPI), and 33 (29.7%) budesonide-formoterol (BUD/F) DPI. Severity of asthma at time of diagnosis, assessed by the treating physician, was comparable among groups. Asthma control was achieved by 45.9% of patients; 38.7% were partially controlled and 15.3% were uncontrolled. In the extrafine BDF/F group, asthma control total score, daytime symptom score and rescue medication use score were significantly better than those using fixed DPI combinations (5.8 ± 6.2 vs. 8.5 ± 6.8; 1.4 ± 1.8 vs. 2.3 ± 2.1; 1.8 ± 2.2 vs. 2.6 ± 2.2; p = 0.0160; p = 0.012 and p = 0.025, respectively) and the mean daily ICS dose were significantly lower.</p> <p>Conclusions</p> <p>pMDI extrafine BDP/F combination demonstrated better asthma control compared to DPIs formulated with larger particles. This could be due to the improved lung deposition of the dose or less reliance on the optimal inhalation technique or both.</p>http://www.biomedcentral.com/1471-2466/11/40inhalerfixed combinationsasthma controlextrafine |
| spellingShingle | Nicolini Gabriele Bizzi Andrea Losonczy György Eszes Noemi Gálffy Gabriella Müller Veronika Chrystyn Henry Tamási Lilla Asthma control in patients receiving inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation BMC Pulmonary Medicine inhaler fixed combinations asthma control extrafine |
| title | Asthma control in patients receiving inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation |
| title_full | Asthma control in patients receiving inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation |
| title_fullStr | Asthma control in patients receiving inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation |
| title_full_unstemmed | Asthma control in patients receiving inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation |
| title_short | Asthma control in patients receiving inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation |
| title_sort | asthma control in patients receiving inhaled corticosteroid and long acting beta sub 2 sub agonist fixed combinations a real life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation |
| topic | inhaler fixed combinations asthma control extrafine |
| url | http://www.biomedcentral.com/1471-2466/11/40 |
| work_keys_str_mv | AT nicolinigabriele asthmacontrolinpatientsreceivinginhaledcorticosteroidandlongactingbetasub2subagonistfixedcombinationsareallifestudycomparingdrypowderinhalersandapressurizedmetereddoseinhalerextrafineformulation AT bizziandrea asthmacontrolinpatientsreceivinginhaledcorticosteroidandlongactingbetasub2subagonistfixedcombinationsareallifestudycomparingdrypowderinhalersandapressurizedmetereddoseinhalerextrafineformulation AT losonczygyorgy asthmacontrolinpatientsreceivinginhaledcorticosteroidandlongactingbetasub2subagonistfixedcombinationsareallifestudycomparingdrypowderinhalersandapressurizedmetereddoseinhalerextrafineformulation AT eszesnoemi asthmacontrolinpatientsreceivinginhaledcorticosteroidandlongactingbetasub2subagonistfixedcombinationsareallifestudycomparingdrypowderinhalersandapressurizedmetereddoseinhalerextrafineformulation AT galffygabriella asthmacontrolinpatientsreceivinginhaledcorticosteroidandlongactingbetasub2subagonistfixedcombinationsareallifestudycomparingdrypowderinhalersandapressurizedmetereddoseinhalerextrafineformulation AT mullerveronika asthmacontrolinpatientsreceivinginhaledcorticosteroidandlongactingbetasub2subagonistfixedcombinationsareallifestudycomparingdrypowderinhalersandapressurizedmetereddoseinhalerextrafineformulation AT chrystynhenry asthmacontrolinpatientsreceivinginhaledcorticosteroidandlongactingbetasub2subagonistfixedcombinationsareallifestudycomparingdrypowderinhalersandapressurizedmetereddoseinhalerextrafineformulation AT tamasililla asthmacontrolinpatientsreceivinginhaledcorticosteroidandlongactingbetasub2subagonistfixedcombinationsareallifestudycomparingdrypowderinhalersandapressurizedmetereddoseinhalerextrafineformulation |